PharmacyCodes



4-04-00-02998 (Beilstein Handbook Reference) en es it fr

4-04-00-02998 (Beilstein Handbook Reference) Brand names, 4-04-00-02998 (Beilstein Handbook Reference) Analogs

4-04-00-02998 (Beilstein Handbook Reference) Brand Names Mixture

  • No information avaliable

4-04-00-02998 (Beilstein Handbook Reference) Chemical_Formula

C4H7N1O4

4-04-00-02998 (Beilstein Handbook Reference) RX_link

No information avaliable

4-04-00-02998 (Beilstein Handbook Reference) fda sheet

4-04-00-02998 (Beilstein Handbook Reference) msds (material safety sheet)

http://domino.solutia.com/solutia/smsdslib.nsf/0/561ad1a8b4bae67c8625636000511152/$FILE/English.pdf

4-04-00-02998 (Beilstein Handbook Reference) Synthesis Reference

No information avaliable

4-04-00-02998 (Beilstein Handbook Reference) Molecular Weight

133.104 g/mol

4-04-00-02998 (Beilstein Handbook Reference) Melting Point

230 oC

4-04-00-02998 (Beilstein Handbook Reference) H2O Solubility

4.5 g/l

4-04-00-02998 (Beilstein Handbook Reference) State

Solid

4-04-00-02998 (Beilstein Handbook Reference) LogP

-0.67 +/- 0.36

4-04-00-02998 (Beilstein Handbook Reference) Dosage Forms

Capsules and powder

4-04-00-02998 (Beilstein Handbook Reference) Indication

There is no support for the claim that aspartates are exercise performance enhancers, i.e. ergogenic aids.

4-04-00-02998 (Beilstein Handbook Reference) Pharmacology

L-aspartate is considered a non-essential amino acid, meaning that, under normal physiological conditions, sufficient amounts of the amino acid are synthesized in the body to meet the body's requirements. L-aspartate is formed by the transamination of the Krebs cycle intermediate oxaloacetate. The amino acid serves as a precursor for synthesis of proteins, oligopeptides, purines, pyrimidines, nucleic acids and L-arginine. L-aspartate is a glycogenic amino acid, and it can also promote energy production via its metabolism in the Krebs cycle. These latter activities were the rationale for the claim that supplemental aspartate has an anti-fatigue effect on skeletal muscle, a claim that was never confirmed.

4-04-00-02998 (Beilstein Handbook Reference) Absorption

Absorbed from the small intestine by an active transport process

4-04-00-02998 (Beilstein Handbook Reference) side effects and Toxicity

Mild gastrointestinal side effects including diarrhea. LD50 (rat) > 5,000 mg/kg.

4-04-00-02998 (Beilstein Handbook Reference) Patient Information

No information avaliable

4-04-00-02998 (Beilstein Handbook Reference) Organisms Affected

Humans and other mammals